◆お知らせ
カテゴリー「妊婦・授乳婦」を参照→
◆ガイドライン
日本産科婦人科学会 (URL)、日本産婦人科医会 (URL)：「産婦人科診療ガイドライン 産科編2014」、p52-105．
大分県地域保健協議会 大分県「母乳と薬剤」研究会：「母乳とくすりハンドブック」、改訂第3版．
入手問い合わせ先）大分県医師会 (URL)、大分県薬剤師会 (URL)
社団法人 愛知県薬剤師会 妊婦・授乳婦医薬品適正使用推進研究班：「妊娠・授乳と薬 対応基本手引き」、改訂第2版．
◆関連学会等
日本産科婦人科科学会 (URL)
国立成育医療センター (URL) ＞妊娠と薬情報センター (URL)
◆妊娠と薬に関するオンラインデータベース
ENTIS（ヨーロッパの催奇形情報提供ネットワーク） (URL)
MotherToBaby (URL)：The Organization of Teratology Information Specialists (OTIS) 北米の催奇形情報提供ネットワークが運営
Reprotox (URL)
Motherrisk (URL)
◆参考資料
書籍
Gerald G Briggs: Drugs in Pregnancy and Lactation, 11ed, Lippincott Williams & Wilkins, 2017/5/17.
伊藤真也 村島温子 編：「薬物治療コンサルテーション 妊娠と授乳」、第2版、南山堂、2014/11/26．
佐藤孝道 林 昌洋 監：「実践 妊娠と薬 第2版 －10,000例の相談事例とその情報」、第2版、じほう、2010/12/10．
論文
2017
Richardson JL et al.: “Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services.”, Reproductive Toxicology, 67, 26-34 (2017). PMID: 27851994 DOI: 10.1016/j.reprotox.2016.11.010
2016
Damkier P et al.: “Changing of the guards: EMA warning on paternal use of mycophenolate mofetil: An unnecessary and insufficiently substantiated precaution.”, Birth Defects Research Part A Clinical and Molecular Teratology, 106 (10), 860-861 (2016). PMID: 27678452 DOI: 10.1002/bdra.23556
Diav-Citrin O et al.: “Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study.”, Journal of Clinical Psychiatry, 77 (9), 1176-1181 (2016). PMID: 27232650 DOI: 10.4088/JCP.15m10083
Winterfeld U et al.: “Pregnancy outcome following maternal exposure to pregabalin may call for concern.”, Neurology, 86 (24), 2251-2257 (2016). PMID: 27194385 DOI: 10.1212/WNL.0000000000002767
2015
Weber-Schoendorfer C et al.: “Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.”, British Journal of Clinical Pharmacology, 80 (4), 727-739 (2015). PMID: 25808588 PMCID: PMC4594709 DOI: 10.1111/bcp.12642
Winterfeld U et al.: “Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.”, Journal of Clinical Psychopharmacology, 35 (3), 250-259 (2015). PMID: 25830592 DOI: 10.1097/JCP.0000000000000309
2014
Weber-Schoendorfer C et al.: “Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.”, Arthritis Rheumatology, 66 (5), 1101-1110 (2014). PMID: 24470106 DOI: 10.1002/art.38368
Lupattelli A et al.: “Medication use in pregnancy: a cross-sectional, multinational web-based study.”, BMJ Open, 4 (2), e004365 (2014). PMID: 24534260 PMCID: PMC3927801 DOI: 10.1136/bmjopen-2013-004365
2013
Winterfeld U et al.: “Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.”, BJOG, 120 (4), 463-471 (2013). PMID:23194157 DOI:10.1111/1471-0528.12066
Comment in;
Vlachadis N et al.: “Statins in pregnancy: safety and perspectives of therapeutic applications.”, BJOG, 120 (11), 1439-1440 (2013).PMID:24034522
Winterfeld U et al.: “Authors’ response to: Statins in pregnancy: safety and perspectives of therapeutic applications.”, BJOG, 120 (11), 1440 (2013). PMID:24034523
2012
Panchaud A et al.: “Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study.”, J Clin Pharmacol., 52 (12), 1844-1851 (2012). PMID:22174426 DOI:10.1177/0091270011429566
Hoeltzenbein M et al.: “Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services.”, American Journal of Medical Genetics, 158A (3), 588-596 (2012). PMID: 22319001 DOI:10.1002/ajmg.a.35223
Bar-Oz B et al.: “The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study.”, Drug Safety, 35 (7), 589-598 (2012). PMID: 22702640 DOI: 10.2165/11630920-000000000-00000
(ENTIS 関連の論文)
